The Hill
Sunday, July 05, 2009
SEARCH
Home
HillTube
Mobile
White Papers Portal
New Member Guide
BLOGS
Pundits Blog
Congress Blog
Blog Briefing Room
Twitter Room Blog
NEWS
Leading The News
Business & Lobbying
K Street Insiders
John Breaux
John Engler
Vin Weber
Dave Wenhold
The Executive
Campaign
Obama Cabinet
COLUMNISTS
Dick Morris
A.B. Stoddard
Brent Budowsky
Ben Goddard
David Hill
David Keene
Josh Marshall
Mark Mellman
Jim Mills
Markos Moulitsas (Kos)
Cheri Jacobus
John Del Cecato
COMMENT
Editorial
Letters
Op-eds
Weyant's World
CAPITAL LIVING
Today's Stories
50 Most Beautiful 2008
Other Features
In The Know
Bookshelf
Announcements
Food & Drink
Onward and Upward
RESOURCES
Classifieds
Subscribe
Order Reprints
Aerospace
Energy Special Report
Telecom Special Report
Transport Special Report
Earth Day Special Report
Consumer Safety Report
Useful Links
RSS


Home arrow Op-eds arrow A simple step to address pharmaceutical costs
Op-eds PDF Print E-mail
A simple step to address pharmaceutical costs
Posted: 09/11/07 06:04 PM [ET]
Michael Moore’s summer hit “Sicko” has brought renewed attention to the flaws in the U.S. health system, including the high cost of prescription drugs. Here are just a few sobering statistics:

• One-fourth of adults 19 to 64 years old lack prescription drug insurance. Those without drug coverage are almost twice as likely not to fill a prescription due to cost.

• Spending in the U.S. for prescription drugs was $201 billion in 2005, almost five times more than the $40 billion spent in 1990.

• The number of prescriptions purchased increased 71 percent over the past decade compared to the U.S. population growth of 9 percent.

At a time when pharmaceuticals play such a key role in the treatment of patients, healthcare providers cannot keep up with the demand for expensive medications. Whether or not you agree with Mr. Moore’s politics or solutions to the healthcare crisis, it is clear our country needs to address the challenges of improving access to pharmaceutical care.

With spending on pharmaceuticals continuing to grow dramatically and the number of uninsured now reaching 47 million, the burden of providing pharmaceutical care to vulnerable patients falls increasingly on our nation’s hospitals, clinics and health centers, particularly those with a charitable care mission. Hospitals that serve high volumes of care to low-income and uninsured patients are able to obtain some relief on their pharmaceutical costs through a federal drug discount program operated by the Public Health Service called the 340B program. The 340B program enables hospitals, community health centers and other government-supported healthcare facilities to access significant discounts on pharmaceuticals. While the discounts through the 340B program are quite significant, they only apply to drugs used on an outpatient basis due to the way the 340B law was written in 1992. As a result, hospitals have to pay an average of 25 percent more for drugs given to patients that are admitted into their facility for an overnight stay. Not only does this result in higher pharmaceutical costs, but hospital pharmacies are also saddled with the burden of managing two pharmacy inventories. This forces hospitals to hire additional staff and purchase costly information systems instead of devoting resources to improving patient care and reducing long lines at the pharmacy counter.

Fortunately, there is an effort to address this problem and provide some assistance to our nation’s charitable hospitals. Bipartisan legislation has been introduced by Sens. Jeff Bingaman (D-N.M.) and John Thune (R-S.D.), and by Reps. Bobby Rush (D-Ill.), Bart Stupak (D-Mich.) and Jo Ann Emerson (R-Mo.) that would extend federal drug discounts to the inpatient setting for these charitable hospitals. The legislation would also create savings for the Medicaid program, the federal-state health insurance program for low-income and disabled patients, by requiring hospitals to share the savings with Medicaid. This legislation certainly would not solve our healthcare woes, but it would go a long way toward ensuring that safety net hospitals in this country can continue their mission of providing care to all patients regardless of their ability to pay.

Slafsky is executive director of Safety Net Hospitals for Pharmaceutical Access, a Washington, D.C.-based nonprofit organization of over 400 hospitals throughout the country that serve high volumes of care to low-income and uninsured patients.
 
 
 
BLOGS
TheHill.com Blogs Briefing Room Pundits Room Congress Blog Twitter Room
ADVERTISER
Home | Privacy Policy | Terms And Conditions
The Hill
1625 K Street, NW Suite 900
Washington, DC 20006
202-628-8500 tel | 202-628-8503 fax

The contents of this site are © 2009 Capitol Hill Publishing Corp., a subsidiary of News Communications, Inc.